Injectable Glutathione Recalls and Illnesses: Federal and Florida Exposure for Med Spas, IV Clinics and Medical Directors

A med spa that pushes glutathione through an IV line is relying on three things it did not make and cannot see: the grade of the powder, the pharmacy's testing, and the pharmacy's process. Federal regulators say one of those failed. FDA has posted voluntary recalls of compounded glutathione injection from more than one Texas pharmacy, citing elevated or potentially elevated bacterial endotoxin. CDC reports more than 25 illnesses across four states, Florida among them. This is not a prosecution, and no one has been charged on these facts. It is a recall and an illness investigation. But recalls and clusters of injuries are how many drug cases begin, and the clinics that bought, stocked and injected the product are the ones with patient records, invoices and standing orders for an investigator to read.

The clinics that bought, stocked and injected the product hold the patient records, invoices and standing orders an investigator will read.

Key Takeaways

• FDA says dietary supplement grade glutathione is not an appropriate ingredient for injectable drugs, and at least 30 patients had reported adverse events as of August 27, 2026.
• Adulterated drugs are barred from interstate commerce by 21 U.S.C. § 331(a); a violation carries up to one year, or up to three years with intent to defraud or mislead, under 21 U.S.C. § 333(a).
• Section 503A, 21 U.S.C. § 353a, exempts compounded drugs from certain requirements only for an identified patient with a valid prescription, which puts office-use stock in question.
• In Florida, Fla. Stat. § 499.005 makes it unlawful to sell, deliver or hold an adulterated drug; Fla. Stat. § 499.0051 grades the penalties by act and knowledge.
• A South Florida med spa that bought or administered recalled lots should preserve records and call counsel before answering any investigator, inspector or board request.

What the Agencies Have Said

On August 27, 2026, FDA published a reminder that dietary supplement grade glutathione is not an appropriate ingredient to make injectable drugs. The agency reported that at least 30 patients had adverse events after receiving intravenous glutathione, alone or combined with other ingredients, and described fever, chills, pain, dizziness, shock-like and sepsis-like symptoms, and some hospitalizations. FDA said it was still investigating.

FDA described fever, chills, pain, dizziness, shock-like and sepsis-like symptoms, and some hospitalizations after intravenous glutathione, alone or combined with other ingredients.

CDC's current-situation page reports more than 25 people ill in Texas, Washington, Florida and New York, with at least three hospitalizations. All three hospitalized patients received glutathione intravenously. One became critically ill and needed intensive care for shock and abnormal blood clotting. The page reports no deaths. CDC's interim guidance tells clinicians not to administer injectable glutathione compounded with dietary supplement grade ingredients, or any product whose ingredient grade cannot be verified.

The recalls are on FDA's site. One, posted in September, covers six lots of 30 mL multidose vials of glutathione, a Myers cocktail and an immune product, and reports nine adverse events. Another, announced October 1, covers ten lots of 10 mL multidose vials shipped nationwide between June 26 and September 21, 2026. Its sponsor reports two patients who needed emergency care after intravenous use of a product it says was not formulated for intravenous use.

What the Government Is Building

Recalls are public. The paper behind them is not. A 503A pharmacy that recalls a product has lot records, ingredient certificates, customer lists and prescriber lists. FDA can inspect the pharmacy, and the customer list tells it which clinics received the product and in what quantity.

Recalls are public. The paper behind them is not. The customer list tells FDA which clinics received the product and in what quantity.

The next question for an investigator is who ordered what, for whom. A patient-specific prescription and a standing order for stock are different documents with different legal consequences. Where the product went into a patient who was hurt, expect state health department contact, a Department of Health inquiry, and, in a serious case, a referral to FDA's Office of Criminal Investigations and the U.S. Attorney's Office. Where the facts are strong enough, the sequence ends with a target letter or a grand jury subpoena. A South Florida clinic that learns it received a recalled lot should treat that as the start of a possible federal investigation, not as a supplier problem.

Federal Exposure: 21 U.S.C. § 331, § 333 and Section 503A

The core federal provision is 21 U.S.C. § 331(a), which prohibits introducing or delivering for introduction into interstate commerce a drug that is adulterated or misbranded. Subsection (b) reaches adulteration or misbranding of a drug while in interstate commerce. A drug is adulterated under 21 U.S.C. § 351(a)(2)(B) if the methods, facilities or controls used to make it do not conform to current good manufacturing practice, and under subsection (a)(2)(A) if it was prepared or held under insanitary conditions that may have rendered it injurious to health.

The penalty is in 21 U.S.C. § 333(a). A violation of section 331 is punishable by up to one year, a fine, or both. The text of that paragraph states no intent element. If the violation is committed with intent to defraud or mislead, the maximum rises to three years and a larger fine. That intent line is where clinic conduct matters most: a false statement to patients about the source, grade or safety of a product, or a false record, moves a regulatory problem toward a fraud problem.

Section 503A matters because it is the pharmacy's defense and the clinic's yardstick. Under 21 U.S.C. § 353a, the exemption from certain requirements applies to a drug compounded for an identified individual patient based on a valid prescription order, by a licensed pharmacist or physician, using bulk drug substances that meet the statute's conditions. Whether a given glutathione ingredient met those conditions is a question for the record, and I do not assume the answer. But a clinic that ordered multidose vials as office stock, without a patient name on each order, has to explain how that fits the identified-patient language.

Florida Law and the Administering Clinic

Florida law runs in parallel and comes first for a Florida clinic. Fla. Stat. § 499.005 makes it unlawful to manufacture, repackage, sell, deliver, or hold or offer for sale an adulterated or misbranded drug, and the adulteration or misbranding of a drug. Fla. Stat. § 499.006 defines adulteration to include a drug produced, prepared, packed or held under conditions that could have contaminated it or rendered it injurious to health. Fla. Stat. § 499.0051 sets the penalties, and the grade turns on the specific act and on what the person knew. In my reading, some adulterated-drug violations are misdemeanors, and knowing distribution of adulterated drugs is charged as a felony. Read the current section against the facts before relying on that summary.

An administering clinic is not the obvious defendant under these statutes. They are written around the maker and the distributor. That changes if the clinic re-vialed or relabeled product, sold it onward, ordered it without patient-specific prescriptions, kept using it after a recall notice, or described it to patients in terms the record does not support. It also changes if a patient is badly hurt. Board discipline and civil claims attach to the clinic and the medical director on far thinner facts than a criminal case needs.

Critical Mistakes People Make Early

Clinics lose ground in the first week. They keep selling from the same shelf. They call the pharmacy and ask for a written statement that the product was fine. They discard remaining vials, which destroys the lot evidence the clinic needs. They answer an inspector's questions informally, in the treatment room, without knowing what the inspector already has. They assume that because no patient complained, nothing is coming.

Strategic Defense Approach

Start with a written hold. Quarantine and label remaining stock in place, with lot numbers, and do not destroy it unless the recall notice and counsel say how. Pull purchase orders, invoices, standing orders, prescriptions, treatment logs and patient consent forms for the affected lots. Identify every patient who received those lots, and decide with counsel how and when to notify them. Do not rewrite a chart.

Then separate the clinic's position from the pharmacy's and from the medical director's. Their interests diverge quickly. The pharmacy will point to its supplier, the clinic to the pharmacy, and the medical director to the owner's standing order. Each position needs its own counsel review before anyone gives a statement. A med spa defense attorney with federal experience can speak to the agencies on the clinic's behalf, and the firm's peptide and compounding practice works the sourcing and 503A questions directly. If a letter or subpoena arrives, see our page on target letter and pre-indictment defense.

Related reading: how federal prosecutors are treating GLP-1, peptide and compounded-drug marketing and why the peptide industry is drawing federal criminal charges.

Why Timing Matters

Recall facts are still moving. FDA said it would post updates, and CDC says its count may change. Charging decisions, if they come, follow the investigation, and the investigation depends on early records. The clinic that preserves its documents, controls what it says, and decides its own position before an agency does keeps the most options.

"The one that waits for a letter finds the record already written by someone else."— Aaron M. Cohen, Principal Attorney

Common Questions

Received or Administered Compounded Glutathione in Florida?

If your clinic bought, stocked or injected a recalled lot, or an agency has contacted you, call AMC Defense Law for a confidential consultation before you answer questions or change any record. Every matter depends on its facts, and nothing in this post predicts or promises an outcome. Contact the firm, call 561-542-5494, or email amc@amcdefenselaw.com. AMC Defense Law, 1200 N. Federal Highway, Suite 300, Boca Raton, Florida 33432.

AMC Defense Law represents med spas, IV clinics and medical directors in federal and Florida compounded-drug investigations.

If you or your loved ones have been arrested or contacted by investigators, call Aaron M. Cohen, 24 hours a day to get help.

About the author. Aaron M. Cohen is the founder and principal attorney of AMC Defense Law, a criminal defense firm in Boca Raton, Florida, with more than 30 years of experience in state and federal courts. He is admitted to practice in Florida, New York, New Jersey, and the District of Columbia, and before the United States District Courts for the Southern and Middle Districts of Florida, the Southern, Eastern, and Western Districts of New York, the District of New Jersey, and the Northern District of Texas. He appears pro hac vice in other federal districts nationwide. The firm represents clients in federal investigations and prosecutions involving healthcare fraud, Anti-Kickback Statute matters, DME and telemedicine fraud, peptide and compounded-drug enforcement, controlled-substance and drug conspiracy cases, financial crimes, and complex federal litigation, in Florida and nationwide.

Disclaimer: This article is for general information only. It is not legal advice and does not create an attorney-client relationship. Laws and agency facts change; the recall and illness figures here were taken from FDA and CDC pages as they read on October 15, 2026. No outcome is guaranteed. Do not rely on this post for a specific situation; consult a lawyer.